Shares of Celyad SA (NASDAQ:CYAD) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Brokers have set a 1-year consensus target price of $49.00 for the company, according to Zacks. Zacks has also assigned Celyad SA an industry rank of 153 out of 265 based on the ratings given to its competitors.

Several equities analysts have recently commented on CYAD shares. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $49.00 price target (up previously from $35.00) on shares of Celyad SA in a research note on Friday, September 1st. BidaskClub lowered Celyad SA from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Finally, ValuEngine raised Celyad SA from a “sell” rating to a “hold” rating in a research note on Thursday, June 29th.

Shares of Celyad SA (CYAD) traded down 0.88% during mid-day trading on Tuesday, reaching $61.92. The company had a trading volume of 1,400 shares. The stock’s 50-day moving average price is $56.66 and its 200 day moving average price is $56.66. The company’s market capitalization is $589.79 million. Celyad SA has a 1-year low of $16.31 and a 1-year high of $64.75.

ILLEGAL ACTIVITY WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2017/10/17/zacks-celyad-sa-cyad-given-consensus-rating-of-strong-buy-by-analysts.html.

About Celyad SA

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.

Get a free copy of the Zacks research report on Celyad SA (CYAD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with MarketBeat.com's FREE daily email newsletter.